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Figure 1. Strigolactones.
Chemical structures of the strigolactone intermediate, carlactone, and representatives, strigol 
and orobanchol, of the two main classes of strigolactone. Where present, the four rings shown 
are designated ABCD, named sequentially from left to right (naming not shown). (B) Arabidop-
sis wild-type (left) and max4 strigolactone deficient mutant (right).shoot branching is inhibited by 
strigolactone. Dependent on 
phosphate and carbon status, 
strigolactones supress root growth 
and adventitious rooting and enhance 
root hairs and nodulation. In the 
shoot, in addition to branching 
inhibition, they affect stem elongation 
(plant height) and secondary growth 
(wood production). 
How do they work? Major 
components of the perception and 
signalling pathway have already 
been revealed. These include an a/ 
hydrolase as receptor and a complex 
of players including a DELLA protein 
and an F-Box protein. In shoots, a 
protein named D53 has been shown 
to be targeted for degradation in the 
presence of strigolactones and this 
degradation is required for branch 
inhibition. The downstream targets 
are not yet proven, but are likely to 
differ for different processes. 
Strigolactone deficiency is often 
associated with enhanced auxin 
transport. For shoots, there is 
ongoing debate about relative roles 
of auxin transport and the direct 
action of strigolactones on other 
pathways such as through Teosinte 
Branched-1 (TB1; other names BRC1 
and FC1). An enhancer of TB1 gene 
expression was identified as the 
main cause of decreased tillering 
and enhanced yield in domesticated maize compared with its wild 
progenitor, teosinte. 
Do they have commercial potential? 
Yes, based on all the effects of 
strigolactone many commercial 
opportunities could arise — wood 
production, shoot architecture, 
adventitious rooting, root 
development, nutrient acquisition, 
parasitic weeds and more. Already 
it is possible to identify certain 
strigolactones that affect one 
process and not another. However, 
one challenge is to identify stable 
strigolactones or methods of 
delivery that enhance stability. The 
opportunities for genetic manipulation 
of the pathway are also clear.
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In the United States alone, one-third 
of adults and nearly one-quarter of 
children are clinically obese. This 
growing epidemic is of serious concern 
as obesity confers a significant risk 
to developing numerous chronic 
conditions, including cancer, diabetes, 
and heart disease. The alarming 
incidence of obesity and the rising 
costs of treating the associated 
diseases has increased the urgency 
of acquiring a deeper understanding 
of all aspects of adipocyte (fat cell) 
biology, including how these cells 
form, how they are regulated, and 
how increased adiposity leads to 
disease. Since the turn of the new 
century we have witnessed great 
progress in understanding the 
complexities of adipocyte function 
and their developmental origin. As 
a result, our view of adipocytes has 
now changed dramatically. Here, I 
provide a brief primer on some of the 
hot topics that have emerged in this 
field of research, which now includes 
aspects of endocrinology, cardiology, 
cancer biology, and stem cell and 
developmental biology. I also highlight 
some of the unique opportunities for 
therapeutic targeting of adipose tissue 
in metabolic disease. 
The many functions of adipocytes
Storage and release of excess energy
In vertebrates, many cell types 
can accumulate lipid; however, the 
evolution of specialized fat-storing 
cells (‘white adipocytes’) has provided 
a safe and specific compartment for 
this purpose. White adipocytes are 
characterized by the presence of 
a single large lipid droplet and are 
therefore also known as ‘unilocular’ 
adipocytes. Their classical function, 
first and foremost, is to serve as an 
energy bank (Figure 1). During times 
of energy excess, free fatty acids 
(FFAs) enter adipocytes following 
the hydrolysis of triglycerides from 
triglyceride-rich lipoproteins and 
chylomicrons. FFAs are then  
re-esterified into triglycerides 
through the sequential actions 
of multiple enzymes, including 
glycerol-3-phosphate acyltransferase 
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acyltransferase (AGPAT), phosphatidic 
acid phosphatase (PAP), and 
diacylglycerol acyltransferase (DGAT). 
Adipocytes can also synthesize 
lipid from carbohydrates through 
de novo lipogenesis. When energy 
levels are low, adipocytes contain the 
enzymatic machinery — comprising 
adipose triglyceride lipase (ATGL), 
hormone-sensitive lipase (HSL), 
and monoglyceride lipase (MGL) — 
required to hydrolyze triglycerides and 
release FFAs back into circulation.
Lipid trafficking in adipocytes has 
been extensively studied for the past 
decade; however, there remains much 
to learn. The principle enzymes in 
adipocyte triglyceride metabolism have 
been identified, although the precise 
function and relative importance of 
these enzymes and their distinct 
isoforms in vivo remain unclear. A 
better understanding of how these 
mechanisms are utilized in human 
adipose tissue, and how they are 
dysregulated in metabolic disease, 
will also be essential. More recently, 
it has become clearer that proteins 
associated with the lipid droplet, such 
as the perilipin family of proteins, play 
an important role in regulating lipolysis 
and lipid metabolism in adipocytes. 
Understanding the precise functions 
of these various proteins and how they 
communicate with other pathways 
within the cell is of great interest. 
Furthermore, lipid intermediates 
themselves can serve as signaling 
molecules in adipocytes, through 
binding to nuclear hormone receptors 
or interacting with second-messenger 
systems. Identifying and characterizing 
these various lipid signals is an 
ongoing challenge in the field.
Endocrine role
For nearly a century, adipocytes were 
appreciated solely for their energy 
storage capacity. This view began 
to change with the discovery that 
adipose tissue in obesity produced 
tumor necrosis factor a (TNF-a), a 
pro-inflammatory cytokine that drives 
insulin resistance; this provided the 
first link between adipose-secretory 
products and insulin resistance in 
obesity. The discovery of the hormone 
leptin was a pivotal point in the field 
of energy metabolism. Leptin is 
produced and secreted by adipocytes 
and functions centrally to regulate 
satiety. Leptin also acts on peripheral 
tissues to control nutrient homeostasis and inflammation. Importantly, this 
discovery provided evidence of a now 
widely appreciated endocrine role 
for adipocytes. Contemporaneously, 
two other ‘adipokines’ (adipocyte-
derived cytokines) — adiponectin and 
adipsin — were identified. Adiponectin 
is produced almost exclusively by 
adipocytes and exerts powerful and 
pleiotropic effects on glucose and 
lipid metabolism, and also provides 
cardioprotection. Adipsin, also 
expressed exclusively in adipocytes, 
acts in an adipose–pancreas inter-
organ axis to regulate the insulin-
secretory capacity of -cells. 
The list of adipokines is growing 
and their widespread effects on 
energy balance, cardiovascular 
function, immune regulation, and 
nutrient homeostasis are becoming 
more and more evident. There is 
tremendous excitement and promise 
in understanding the wide range of 
physiological roles for these adipose 
secretory proteins because many 
adipokines exhibit therapeutic 
potential. However, the complexity of 
their action also represents a challenge 
for the design of effective and specific 
treatments. Going forward, the specific 
mechanisms by which adiponectin, 
leptin, and other adipokines elicit their 
functions in different target tissues 
will need to be further elucidated. 
Moreover, the relative importance 
of many of these factors remains 
unclear. Targeted deletions of cognate 
receptors or target pathways in animal 
models will ultimately help provide 
insight into the precise roles of many of 
these adipokines. 
Thermogenic adipocytes: brown and 
beige
In addition to the energy-storing 
white adipocytes described above, all 
mammals have a second major type 
of adipocyte that functions to convert 
chemical energy into heat. These 
thermogenic ‘brown adipocytes’ are 
characterized by their abundance 
of mitochondria (which give the 
cells their brown appearance) and 
multilocular fat droplet appearance 
(Figure 1). Distinct depots of brown 
adipose tissue (BAT) are most 
abundant in the interscapular region 
of small mammals and infants, 
and develop during embryonic 
development. Brown adipocytes 
likely evolved to help defend animals 
against the cold and were historically 
referred to as the ‘hibernating organ’ due to their function in maintaining 
body temperature in hibernating 
animals and newborns. 
Brown-like adipocytes also 
appear within distinct white adipose 
depots as dispersed pockets of 
multilocular cells. These cells, 
now termed ‘beige adipocytes’, 
represent recruitable thermogenic 
cells that arise in response to cold 
challenge, exercise, and under 
pathological conditions such as 
cancer-associated cachexia. Beige 
fat cells play a meaningful role in the 
regulation of glucose homeostasis 
and energy balance. These cells, 
although thermogenic, appear to be 
molecularly and developmentally 
distinct from brown adipocytes that 
form during development (often 
termed ‘classical BAT’). Adult humans 
contain appreciable amounts of 
active thermogenic adipose tissue; 
molecular analyses suggest that this 
tissue closely resembles the rodent 
beige fat, but also has some features 
of classical brown adipocytes. 
The thermogenic function of brown 
and beige adipocytes is mediated 
by the specific expression of 
uncoupling protein 1 (UCP1). UCP1 
is a transport protein that sits within 
the inner membrane of mitochondria 
and catalyzes a proton leak across 
the inner membrane, dissipating 
the electrochemical gradient that 
has been generated via the electron 
transport chain, thereby uncoupling 
oxidative metabolism from ATP 
synthesis. Heat production occurs as 
the biochemical reactions involved 
in mitochondrial fuel oxidation are 
subsequently accelerated. Tremendous 
effort is focused towards identifying 
‘druggable’ regulators of UCP1 
expression or activity. 
In rodents, BAT is densely 
innervated; the thermogenic program 
is critically regulated by -adrenergic 
signaling in brown adipocytes. The 
story of beige adipocyte activation in 
subcutaneous white adipose tissue 
(WAT) has become more interesting 
and complex. In response to the cold, 
beige adipocytes arise mostly through 
de novo fat cell differentiation, rather 
than through a direct conversion 
of mature white adipocytes into 
UCP1+ cells. Local catecholamine 
production occurs in alternative 
macrophages within WAT, activated by 
eosinophil-derived interleukin-4 (IL-4). 
This immune cell cascade appears 
critical for cold-induced beige cell 
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Location in
humans 
Developmental
origin
‘Unilocular’ fat droplet
Lipid storage 
Production of endocrine
hormones regulating 
nutrient homeostasis, 
food intake, 
cardiovascular function, 
and inflammation
Tissue regeneration
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organized into 
anatomically distinct
depots
Widespread: 
organized into 
anatomically distinct
depots
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droplets; high
mitochondrial
content; UCP1+
‘Multi-locular’ fat
droplets; high
mitochondrial
content; UCP1+ upon
activation
Adaptive thermogenesis 
Regulation of nutrient
homeostasis
Organized as 
distinct depots in
interscapular,
axillary, and peri-
renal regions
Interscapular region in 
infants; cervical, 
supraclavicular, 
axillary, and 
paravertebral regions 
in adults
Myf5+/Pax7+
dermomyotomal 
precursors
Adaptive thermogenesis
Regulation of nutrient
homeostasis
Induced and 
interspersed   within 
white adipose tissue
More abundant in 
inguinal WAT than 
gonadal WAT
Interspersed among 
brown and white 
adipocytes in cervical, 
supraclavicular, 
axillary, and 
paravertebral regions 
in adult
Smooth muscle-like
origin in adults
White adipocytes
Brown adipocytes
Beige adipocytes
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Figure 1. Properties of adipose tissue in rodents and humans.recruitment in rodents. An exercise-
induced muscle-derived hormone, 
meteorn-like, activates this cascade 
to stimulate ‘browning’ of WAT. Many 
other hormones and secreted factors 
promote beige adipocyte formation in 
WAT, including the myokines irisin and 
-aminoisobutyric acid, the cardiac 
peptides ANP, BNP, and cardiotropin-1, 
as well as bile acids, fibroblast growth 
factor 21 (FGF21), and vascular 
endothelial growth factor A (VEGFA). 
Anatomically distinct adipose depots
White adipocytes can appear 
throughout the body but are mostly 
organized into distinct tissues, or 
‘depots’. The major white adipose 
depots can be divided on the basis of 
their anatomical location — visceral 
or subcutaneous. The importance of 
these anatomically distinct depots has 
been demonstrated by clinical studies 
that strongly indicate a correlation 
between adipose tissue distribution 
(rather than simply overall mass) and 
risk for metabolic and cardiovascular disease. Those individuals who 
preferentially accumulate adiposity in 
the visceral/abdominal region are more
prone to developing insulin resistance, 
cardiomyopathy, and certain cancers 
when compared with equally obese 
individuals whose adiposity is 
distributed to more subcutaneous 
regions (e.g. arms, legs, and buttocks). 
In fact, subcutaneous adiposity 
appears to provide a protection 
against metabolic disease. It should be
noted that, in the complete absence 
of adipose tissue (i.e. lipodystrophy), 
insulin resistance and other chronic 
disorders ensue. This has led to a 
notion that perhaps there is ‘good’ 
white fat and ‘bad’ white fat. 
The mechanisms linking visceral 
adiposity to metabolic disease are 
of great interest given the rising 
epidemic of obesity. Certainly part 
of the explanation could be related 
to anatomical location and blood 
flow; visceral adipocytes lie in closer 
proximity to key tissues of nutrient 
homeostasis (e.g. gut, liver, and  
 
pancreas). Transplantation studies, 
however, suggest an alternative or 
parallel explanation. Transplantation 
of visceral adipose tissue into 
subcutaneous regions still leads to 
metabolic dysfunction. This suggests 
that the maladaptive properties of 
visceral WAT are at least in part 
depot-intrinsic. The key question 
is whether differences between the 
depots are due to the cellularity of the 
tissue (smaller healthier adipocytes 
vs. hypertrophic fat cells), presence 
of non-parenchymal cell types (e.g. 
pro-inflammatory macrophages), 
or intrinsic differences at the level 
of the fat cell itself. The latter 
hypothesis is supported by a number 
of recent observations showing that 
anatomically distinct adipocytes 
arise from distinct developmental 
origins, and that anatomically distinct 
adipocytes have vastly different gene 
expression programs. The precise 
functional differences between 
subcutaneous white adipocytes and 
visceral white adipocytes remain 
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current thinking is that multiple types 
of energy-storing white adipocytes 
may exist, just as there are multiple 
types of thermogenic fat cells. 
Another important question 
is how body fat distribution is 
controlled. Preferential expansion of 
subcutaneous adipose tissue in the 
legs and buttocks is more frequently 
observed in females (‘pear shape’ 
obesity). The ‘apple shape’ or visceral 
adiposity is prominent amongst males. 
Sex hormones, particularly estrogen, 
appear to play a key role in this 
process. Understanding how adipose 
tissue distribution is regulated may 
lead to novel therapeutic treatments 
for chronic disease (Figure 2). 
Lastly, it is worth noting that 
adipocytes exist outside of the major 
depots and accumulate ectopically 
within the parenchymal population of 
other tissues and organs. Adipocytes 
can accumulate in the skeletal muscle, 
particularly following muscle injury. 
Likewise, adipocytes exist in the bone 
marrow and accumulate with age. 
Less is known regarding the function 
and properties of these adipocytes. 
However, bone marrow adipocytes, 
in particular, are not inert; these 
cells produce adiponectin at levels 
significant enough to exert systemic 
effects. Understanding the precise 
properties of these lesser-studied 
adipocyte populations may help 
elucidate additional functions of fat 
cells in physiology and homeostasis. 
Adipose development
Transcriptional control of adipocyte 
differentiation
A vast majority of the current 
knowledge of adipocyte development 
is derived from cellular studies of 
adipocyte differentiation. Since 
the 1970s, fat cell differentiation, 
or ‘adipogenesis’, of immortalized 
fibroblast cell lines has been an 
extensively studied model of cellular 
differentiation. Of the available cell 
lines, the 3T3-L1 pre-adipocyte 
cell line remains the most widely 
used cellular model system. 3T3-
L1 cells are highly committed to 
the adipose lineage. Treatment of 
confluent cultures with a hormonal/
pharmacological cocktail consisting 
of dexamethasone, iso-butyl-methyl-
xanthine, and insulin (generally 
referred to as ‘DMI medium’) results 
in efficient differentiation into white 
adipocytes. Importantly, these in vitro derived cells largely, but not entirely, 
resemble bona fide adipocytes found 
in vivo. 
Perhaps the most important 
information to emanate from these 
cellular studies is the vast network of 
transcription factors that coordinate 
the differentiation and maintenance 
of the adipocyte fate. Numerous 
transcriptional components that are 
involved in adipogenesis have been 
described. However, at the center of 
the network is the nuclear hormone 
receptor peroxisome proliferator 
activated receptor g (PPARg), 
which is widely accepted as the 
‘master regulator’ of adipogenesis. 
Its expression is low in adipose 
precursors but is dramatically 
upregulated during adipogenesis. 
Once activated, PPARg participates 
in very powerful positive feedback 
loops, creating a ‘snowball effect’ 
that enhances commitment to the 
adipocyte fate. PPARg directly 
activates its own expression and 
also activates the expression of 
its upstream regulator, CCAAT/
enhancer binding protein a (C/EBPa), 
or transcriptional partners, such as 
the Groucho/Grg/TLE family member 
TLE3. Importantly, PPARg is sufficient 
to drive the full adipogenic program in 
mesenchymal cells and is absolutely 
essential for adipocyte formation in 
rodents and humans.
The factors described above 
represent a ‘core’ transcriptional 
program that guides the terminal 
differentiation of adipocytes, white 
or brown. Tremendous effort is 
now placed on identifying the 
transcriptional mechanisms guiding 
the formation of depot-specific 
adipocytes. Progress has been made 
in identifying key brown and beige 
adipocyte determination factors. 
Expression of transcription factors, 
such as EBF2, PRDM16, and PPAR-g 
coactivator 1a (PGC-1a), is enriched in 
brown and beige adipocytes compared 
with white adipocytes and functions 
to regulate the thermogenic program 
of these fat cells. Most recently, 
the transcription factor interferon 
regulatory factor 4 (IRF4) has been 
implicated in thermogenic gene 
regulation in adipocytes, serving as the 
key transcriptional partner of PGC-1a. 
On the other hand, TLE3 is selectively 
expressed in white adipocytes and 
antagonizes the thermogenic gene 
program and promotes lipid storage. 
Less is known about the transcriptional mechanisms that determine a 
subcutaneous or visceral white 
adipocyte cell fate; however, recent 
studies have identified forkhead box 
protein A3 (Foxa3), Wilm’s tumor 1 
(WT1), and short stature homeobox 2 
(Shox2) as depot-selective regulators 
of adipogenesis or adipocyte function, 
with Foxa3 and WT1 having gonad-
specific roles and Shox2 an inguinal-
specific role. 
The 3T3-L1 and primary pre-
adipocyte cell lines have been 
instrumental in defining the 
transcriptional network that controls 
the terminal differentiation into 
adipocytes. In recent years, emphasis 
has been placed on elucidating the 
early transcriptional events that 
control the initial commitment of pre-
adipocytes to the adipose lineage. The 
multi-C2H2 zinc-finger protein Zfp423 
is one transcriptional determinant of 
preadipocyte commitment. Zfp423 
induces adipose lineage commitment, 
at least in part, by regulating 
preadipocyte levels of PPARg. Zfp423 
expression during adipogenesis 
is repressed by the highly related 
factor Zfp521, which acts as a 
repressor of adipogenesis while 
promoting osteoblast differentiation. 
Zfp521 exerts this function through 
interaction with EBF1, another 
transcription factor required for early 
adipose commitment. Tcf7l1 also 
serves as an important regulator of 
adipogenic lineage commitment: this 
transcriptional repressor regulates 
the expression of cytostructural 
genes and coordinates cell shape or 
cell–cell contact with the activation of 
adipogenesis. 
The cellular models of adipogenesis 
have provided great insight into the 
cellular and transcriptional machinery 
controlling adipocyte differentiation. 
One big challenge going forward is to 
determine the relative importance of 
these factors in vivo, within specific 
fat depots. Adipogenesis occurs 
at both the embryonic stage and in 
adult animals under different contexts 
(e.g. obesity, cold exposure, and 
injury). Whether there are temporal 
requirements for the identified 
adipogenic factors remains unclear. 
Excellent tools are now available for 
Cre–loxP-mediated gene targeting in 
terminally differentiated adipocytes in 
mice. One example is the adiponectin–
Cre transgenic mouse line, which 
expresses Cre recombinase under 
the control of the adiponectin gene 
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Figure 2. Manipulating adipose development to combat chronic disease.
(A) Increasing the number of fat cells, rather than the size of fat cells, in the face of positive en-
ergy balance may lead to healthier adipose tissue in the obese setting. (B) Likewise, directing 
excessive energy towards subcutaneous adipose, rather than visceral regions, may help im-
prove metabolic health in the setting of obesity and lower the risk for cardiometabolic disease 
and cancer. (C) Direct reprogramming of white preadipocytes/adipocytes into energy-burning 
brown/beige adipocytes may be an effective treatment for weight loss or insulin resistance in 
the setting of obesity. Inhibiting the formation of thermogenic adipocytes or converting them to 
white adipocytes may help combat cancer cachexia.promoter. However, specific Cre lines 
that target adipose precursors are 
still needed. Furthermore, genetic 
models that allow depot-specific 
WAT targeting are also required. It is 
likely that these tools will eventually 
evolve from a better understanding of 
the molecular properties of adipose 
precursor cells and the ontogeny of 
fat cells in vivo.
Sorting out the adipose lineage
Most have long believed that all 
adipose depots are mesenchymal in 
origin, and closely related in lineage. 
However, in recent years, modern 
Cre–loxP-mediated lineage-tracing 
approaches have shed light on the 
complexity of adipose development. 
It is now clear that anatomically 
distinct brown and white adipose 
depots arise from vastly distinct 
precursor populations, and at different 
times. In mice, craniofacial WAT, 
but not peripheral fat depots, is derived from a neural crest lineage. 
Gonadal and mesenteric WAT, but 
not subcutaneous depots, descend 
from WT1-expressing mesothelium. 
Brown adipocytes, but not most 
white adipocytes, descend from a 
Myf5+/Pax7+ skeletal-muscle-like 
lineage. Interestingly, most beige 
adipocytes do not arise from a 
Myf5+/Pax7+ lineage; these cells 
share characteristics with and 
descend from a smooth-muscle-like 
lineage. Temporally, inguinal white 
adipocytes and classical brown 
adipocytes develop almost entirely 
during embryogenesis, with lipid 
filling occurring postnatally. Gonadal 
and other visceral WAT develops 
postnatally. It should be noted that 
many assume that individual WAT 
depots arise from a singular source. 
Further analyses of Myf5 and Pax3 
lineage-tracing experiments suggest 
a significant heterogeneity in the 
developmental origin of anatomically distinct fat depots; many WAT depots 
contain both Myf5+/Pax3+ and 
Myf5–/Pax3– adipocytes. Additional 
studies will be required to determine 
whether these distinct populations of 
adipocytes within individual fat depots 
are actually functionally distinct. 
A significant barrier to advancing our 
understanding of adipose development 
is the lack of genetic tools suitable 
to identify, isolate, and manipulate 
distinct adipose precursor cell 
populations in vivo. In recent years, 
a number of approaches have been 
used to tackle this problem. Most 
notably, a number of laboratories have 
successfully combined fluorescence-
activated cell sorting analysis with 
candidate stem cell markers to reveal 
hierarchical populations of highly 
adipogenic adipose precursor cells. 
Adipogenic cells are of non-endothelial 
and non-hematopoietic origin (CD31– 
CD45–) and express stem/surface cell 
markers, such as Sca1, CD34, CD29, 
and platelet-derived growth factor 
a (PDGFRa). A more primitive ‘stem 
cell’ subpopulation can be identified 
from this pool on the basis of CD24 
expression. Importantly, lineage-tracing 
approaches reveal that adipocytes 
descend from cells that express 
PDGFRa at some stage during their 
genesis; this includes adipocytes 
formed during development as well as 
new fat cells formed in adult animals. 
However, it is not clear whether the 
adipose precursor cells found in adult 
WAT are identical to those found in 
the embryo. Other approaches utilize 
transgenic reporter strains in which the 
expression of fluorescent proteins is 
driven by the locus of key regulators 
of adipose lineage commitment (e.g. 
PPARg, Zfp423, and pre-acdipocyte 
factor 1 (Pref-1)). The combined 
use of many of these new reagents 
should allow for the identification of 
hierarchical populations of adipose 
precursor cells and provide insight into 
how these different cell populations are 
regulated spatially and temporally. 
Adipose tissue remodeling and 
dysfunction in chronic disease
Cardiometabolic disease
Obesity confers significant risk for 
developing metabolic disorders; 
however, upwards of one-third of 
obese individuals are resistant to 
developing metabolic syndrome, 
at least for a period of time. This 
suggests that additional factors, 
outside of increased adiposity per 
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obesity. Tremendous insight into 
these determinants has been gained 
by comparing obese individuals 
with metabolic syndrome (Obese-
MetSyn) with obese individuals 
who are relatively metabolically 
healthy (Obese-Healthy). Emerging 
from these studies, as well as from 
numerous rodent studies, is a now 
widely accepted model in which the 
manner by which WAT remodels in 
response to caloric excess is a critical 
determinant of metabolic disease. 
In principle, the expansion of fat 
mass can occur by two mechanisms: 
increased triglyceride storage in 
existing adipocytes, leading to 
‘adipocyte hypertrophy’ (enlargement 
of cell size); or increased formation 
of new adipocytes, or ‘adipocyte 
hyperplasia’ (Figure 2). 
In Obese-MetSyn individuals, WAT 
expands predominantly through 
adipocyte hypertrophy, rather than 
adipocyte hyperplasia. Enlarged fat 
cells outstrip their vascular supply and 
become hypoxic, leading ultimately 
to tissue fibrosis, inflammation, 
and adipocyte apoptosis. These 
‘overworked’ fat cells reach their 
storage capacity; this leads to the 
deleterious accumulation of lipids 
in peripheral tissues unequipped 
to handle excess energy storage 
(termed ‘lipotoxicity’). Moreover, these 
adipocytes become dysfunctional; they 
fail to produce protective adipokines, 
such as adiponectin, and overproduce 
pro-inflammatory cytokines that 
can trigger systemic inflammation, 
cardiac dysfunction, and insulin 
resistance. However, in Obese-Healthy 
individuals WAT expansion through the 
recruitment of new fat cells leads to 
adequate storage of excess triglyceride 
over numerous adipocytes; this limits 
the stress put on individual fat cells 
and preserves their function, delaying 
adipose inflammation, fibrosis, and 
ectopic lipid deposition. In this model, 
metabolic syndrome in obesity is 
related to a relative deficiency of 
functional adipocytes, despite the 
elevated adiposity. In accordance with 
this model, the metabolic sequelae 
of obesity are actually similar to 
those observed in lipodystrophic 
individuals who completely, or almost 
completely, lack adipocytes altogether. 
In this regard, healthy adipocytes are 
protective against metabolic disease 
and cardiac dysfunction, serving as a 
‘lipid sink’ for excess energy. Cancer
There is a growing body of evidence 
from both clinical and preclinical 
studies that indicates that increased 
adiposity is associated with elevated 
incidence, morbidity and mortality 
of numerous cancer subtypes. 
While there is tremendous interest in 
understanding how obesity links to 
cancer progression at the molecular 
level, the precise mechanisms remain 
unclear. In principle, the effects 
on tumor growth or metastasis in 
obesity can be secondary to the 
metabolic sequelae, including elevated 
insulin/insulin-like growth factor 
(IGF) signaling or hyperglycemia. 
However, intriguing data point also to 
the adipose tissue itself as a direct 
regulator of tumor growth. The adipose 
tissue microenvironment, including 
vascular-associated stromal cells and 
various immune cell populations, may 
influence tumor cells. For instance, 
rodent models of liver and colon 
cancer indicate that obesity-related 
chronic inflammation, mediated by 
IL-6 and TNF-a, contribute to tumor 
initiation and progression. Clinical 
studies as well as cellular analyses 
have implicated adipokines, such as 
leptin and adiponectin, in ovarian, 
breast, colon, and other types of 
cancer. Additional studies of how 
adipocyte-derived products regulate 
tumor cell biology will be essential 
to unveil the precise links between 
adipose tissue in obesity and cancer. 
It should be noted that the 
conversation between adipose tissue 
and tumor cells is not one-sided; 
tumors can have a tremendous 
impact on adipose tissue function. In 
particular, many cancer patients suffer 
from cachexia, a debilitating condition 
characterized by the significant loss of 
muscle and fat mass due to increased 
energy expenditure. In rodents and 
humans, cachexia is associated with 
‘browning’ of the adipose tissue. The 
induction of the thermogenic program 
in fat is required for the cachectic 
effects of tumors and appears to be 
mediated, at least in part, by tumor-
derived parathyroid-hormone-related 
protein signaling. This new insight 
now suggests a viable strategy to 
combat cancer cachexia and improve 
patient survival. Moreover, a deeper 
understanding of how the beige fat 
program can develop in this context 
may lead to new strategies both to 
enhance the thermogenic function 
of fat in obesity and diabetes and to inhibit this program in cachectic 
individuals (Figure 2).
Conclusions
For most of the 20th century, white 
adipocytes were viewed as mere 
energy-storing cells that served as a 
fuel bank. It is now clear that adipocytes 
are quite complex and regulate 
many facets of energy metabolism, 
physiology, and disease. Moreover, it 
appears that multiple types of brown 
and white adipocytes exist, each with 
distinct developmental origins. This 
extraordinary complexity creates 
many great opportunities for unique 
therapeutic intervention. Adipokine-
based therapies remain attractive for 
the treatment of cardiovascular disease 
and insulin resistance. Furthermore, 
our increasing knowledge of adipocyte 
development may inform novel 
strategies for manipulating the fate and 
function of brown and white adipocytes 
(Figure 2). Our view of adipocytes has 
changed entirely over the past twenty 
years alone. It is almost certain that 
many more surprises are in store for the 
future.
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